ClinicalTrials.gg
RecruitingNCT06982352Updated Dec 19, 2025

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

A Phase 1 interventional study of LPX-TI641 and Placebo in Atopic Dermatitis (AD) and Psoriasis (PsO), sponsored by LAPIX Therapeutics Inc.. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by LAPIX Therapeutics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Planned enrollment
349th of 544
48 · median 96
Started
2025
with 40 others
Phase 1
82 of 639
10 open now
Primary completion
2026-01
later than 9 of 115 live
Registered
589th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 349th largest by planned enrollment of the 544 interventional ones that give a count, is one of 41 that started in 2025, is one of 82 in phase 1, reaches primary completion later than 9 of the 115 other live ones, and was the 589th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.

Read the detailed description

This is a Phase 1b, multi-center, randomized, double-blind, parallel-group, placebo-controlled multiple dose study in participants with atopic dermatitis or psoriasis.

There will be 2 cohorts, one for each indication. Each cohort will consist of \~ 16-24participants (Total \~up to 48 participants).

The Primary objective of the study is to evaluate the safety and tolerability after multiple oral doses of LPX-TI641 in participants with AD and PsO.

And the secondary objective of the study is to evaluate the plasma pharmacokinetics after multiple oral doses of LPX-TI641 in participants with AD and PsO.

03

Conditions studied

  • Atopic Dermatitis (AD)
  • Psoriasis (PsO)

Keywords

  • phase 1 study
  • safety
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has signed an Form (ICF) prior to any study-specific procedures being performed
  2. ≥ 18 years old, irrespective of their race and ethnicity.
  3. (BMI) 18.0-40.0 kg/m2, inclusive, at screening.
  4. Participants are willing and able to adhere to study protocol requirements and restrictions including but not limited to scheduled outpatient visits, inpatient stay, laboratory tests, and 12-lead ECGs.
  5. The subject must be judged to be in good health by the investigator to participate in the study, based on clinical evaluations, including laboratory safety tests, medical history, physical examination, vital signs and 12-lead completed at the screening visit and prior to the first dose of study drug.
  6. Female subject is (at least 1 year; to be confirmed by FSH if less than 2 years since last menstrual period), permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) or if of and engaged in sexual activity that can result in pregnancy must agree to use any two of the highly effective methods listed below. Male participants with a partner of childbearing potential must also agree to use any two of the highly effective contraception methods listed below between them and their partner. This criterion must be followed from screening visit to 6 weeks after the last dose in females and for 90 days after the last dose for males.

    The following applies to all female participants with childbearing potential and female partners of male participants enrolled in the study.

    1. Implantable progestogen-only hormone contraception associated with inhibition of ovulation.
    2. Intrauterine device.
    3. Intrauterine hormone-releasing system.
    4. Bilateral tubal occlusion.
    5. Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation:
    6. Oral
    7. Intravaginal
    8. Transdermal
    9. Injectable
    10. Progestogen-only hormone contraception (oral or injectable) associated with inhibition of ovulation.
    11. Vasectomized partner
    12. Sexual abstinence -this is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated about the duration of the study and the preferred and usual lifestyle of the participant.
    13. A combination of male condoms with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods)

      The following applies to all male participants in the study:

    14. Sexual abstinence- this is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence must be evaluated for the study and the participant's preferred and usual lifestyle.
    15. A combination of male condoms with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods).
    16. Vasectomy
  7. Negative serum B-human chorionic gonadotropin test at screening (for all females) and negative urine pregnancy at randomization (Day 1) (females of childbearing potential) prior to administration of product.

    For Atopic Dermatitis Cohort:

  8. Diagnosis of AD at least 12 months prior to screening, as defined by the American Academy of Dermatology: Guidelines of care for the management of atopic dermatitis (Eichenfield 2014):

    1. EASI score ≥ 16 at Screening and baseline (Day 0)
    2. vIGA score of ≥3 at screening and baseline (Day 0)
    3. ≥10% of body surface area (BSA) involvement at screening and baseline (Day 0)
    4. Peak pruritis NRS≥4 (average score of daily scores 7 days before Day 0)
  9. History, documented by a physician and/or investigator, of inadequate response to existing topical medications within 6 months preceding screening, or history of intolerance to topical therapy as defined by at least 1 of the following:

    1. Inability to achieve good disease control defined as mild disease or better (e.g., IGA≤2) after use of at least a medium potency topical (TCS) for at least 4 weeks, or for the maximum duration recommended by the product prescribing information (e.g. 14 days for super potent TCS), whichever is shorter (Note: a TCS may be used with or without topical calcineurin inhibitors [TCNIs])
    2. Documented history of adverse reactions with the use of TCS, such as skin atrophy, allergic reactions, or systemic effects that, in the opinion of the investigator, outweigh the benefits of retreatment
    3. Failed systemic therapies intended to treat AD within 6 months preceding screening (will be considered as having inadequate response to topical therapy)
  10. Documented history of clinically significant adverse reactions with the use of TCS, such as skin atrophy, allergic reactions, or systemic effects that, in the opinion of the investigator, outweigh the benefits of retreatment

    For Plaque Psoriasis Cohort:

  11. Confirmed diagnosis of plaque psoriasis for at least 6 months prior to baseline (Day 0)
  12. Plaque psoriasis involving ≥10% body surface area (BSA) in the affected skin other than the face and scalp at screening and baseline (Day 0)
  13. Static Physician's Global Assessment (sPGA) score ≥3 at screening and baseline (Day 0)
  14. PASI score of ≥12 at screening and baseline (Day 0)
  15. Subject must be candidate for phototherapy or systemic therapy
  16. Subject had no significant flare in psoriasis for at least 3 months before screening

Exclusion criteria

Exclusion Criteria:

  1. History of medical conditions or any other reason that in the opinion of the PI would interfere with subject's participation in this study
  2. History of clinically significant drug or alcohol abuse per the PI's opinion within the last 6 months.
  3. Pregnant or lactating women or women currently undergoing infertility treatments or women who intend to become pregnant during the time of study or for 6 weeks after last dose.
  4. Presence of skin comorbidities that would interfere with study assessment or response to treatment
  5. Any known history of within 5 years other than completely treated non- basal cell carcinomas or squamous cell carcinomas of the skin or localized carcinoma in situ of the cervix.
  6. Patients who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics
  7. Symptomatic herpes zoster within 3 months of screening
  8. For the plaque psoriasis cohort,

    1. Unstable forms of PsO (acute guttate PsO, psoriatic erythroderma, generalized pustular PsO, or other unstable form as judged by the investigator), or drug-induced psoriasis.
    2. History of any non-PsO disease that required treatment with oral or parenteral for more than 2 weeks within the past 24 weeks prior to signing the form (ICF)
  9. Receipt of an therapy less than 3 months or 5 drug-elimination half-lives (whichever is longer) prior to first administration of study treatment and during the study
  10. Use of the following topical medications/emollients which could affect assessment of disease activity for at least 2 weeks prior to baseline (Day 0) and throughout the study:

    1. Topical corticosteroids or topical immune modulators (e.g. tacrolimus or pimecrolimus)
    2. Topical phosphodiesterase type 4 (PDE 4) inhibitor or JAK inhibitors or aryl hydrocarbon receptor agonists
    3. Topical or systemic antihistamines
    4. Use of emollients.
  11. Receipt of any of the following excluded therapies as per below and throughout the study:

    1. Oral retinoids within 2 weeks of Day 0
    2. Systemic /immunomodulating therapy (such as but not limited to systemic glucocorticoids, cyclosporine, mycophenolate mofetil, methotrexate, azathioprine, apremilast, or oral JAK inhibiting agents or phototherapy within 4 weeks before screening visit. Stable dose of max 1200ug inhaled budesonide (or equivalent) is allowed.
    3. Any cell depleting therapy, anti-CD4, anti-CD5, anti-CD3 other than anti-CD20 such as rituximab, ocrelizumab, and ofatumumab. Patients who have received rituximab or other selective B lymphocyte depleting agents (including experimental agents) are eligible if they have not received such therapy for at least 1 year prior to screening
  12. Biologics dugs including, but not limited to dupilumab, tralokinumab, ustekinumab, secukinumab, ixikizumab, anti-TNF inhibitors within 8 weeks or 5 drug elimination half-lives whichever is longer and throughout the study
  13. Failed biologics due to efficacy including, but not limited to dupilumab, tralokinumab, ustekinumab, secukinumab, ixikizumab, anti-TNF inhibitors
  14. PUVA or UVB phototherapy within 4 weeks prior to Day 0 and throughout the study.
  15. Subject has clinical or laboratory evidence of active or latent tuberculosis (TB) infection at screening as assessed by QuantiFERON-TB-Gold or a purified protein derivative skin test or equivalent (or both if required per local guidelines) and chest X-ray. Chest X-rays taken within 2 months prior to screening may be used instead of during screening if there is documentation showing no evidence of infection or malignancy as read by qualified physician.
  16. Any active or recurrent infection within 1) the past 8 weeks prior to screening requiring IV/hospitalization or 2) the past 2 weeks prior to screening requiring oral antibiotics.
  17. Laboratory values of the following at the Screening Visit:

    1. \< 11 g/dL
    2. WBC \<3.5X109/L
    3. (ANC) \< 1500 cells/µL, (or \< 1200 cells/µL for participants of African descent who are black)
    4. or alanine aminotransferase > 2.0 x the (ULN) or >= ULN;
    5. Bilirubin > ULN
    6. \< 100,000 cells/[mm\^3] (10\^9/L)
    7. Clinically significant abnormal screening laboratory results as evaluated by the Investigator
  18. Acutely worsened renal function within past 3 months prior to screening or estimated by CDK-EPI creatinine equation with adjustment for body surface area \<60ml/min.
  19. Subject has any clinically significant finding on 12-lead at screening or admission. NOTE: (F) interval of >450 msec in male participants or >470 msec in female participants will be the basis for exclusion from the study. ECG may be repeated once for confirmatory purposes if initial values obtained exceed the limits specified.
  20. Subject with positive results for (hepatitis B surface antigens) and/or HBcAb (Hepatitis B core antibodies) and/or Ab (hepatitis C antibodies) confirmed by HCV RNA, and/or Ab (human immunodeficiency virus antibodies).
  21. Blood loss of >250 mL or donated blood within 56 days or donated plasma within 7 days of screening.
  22. Recent vaccination with such as influenza, MMR, Herpes zoster, varicella, yellow fever, Rotavirus vaccine, etc., or inactivated vaccines such as Hepatitis A, rabies vaccine, etc. 30 days prior to screening visit
  23. Subject has known sensitivity to any of the components of the investigational product.
  24. Subject is investigative site personnel, sponsor personnel, or a member of their immediate families (spouse, parent, child or sibling whether biological or legally adopted).
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Psoriasis

    LPX-TI641 or Placebo

    Drug: LPX-TI641 · Drug: Placebo

  • Experimental
    Atopic dermatitis

    LPX-TI641 or Placebo

    Drug: LPX-TI641 · Drug: Placebo

Interventions

  • DrugLPX-TI641

    Oral administration QD for 28 consecutive days

  • DrugPlacebo

    Placebo an identical oral formulation without the LPX-TI641.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability after multiple oral doses of LPX-TI641 in participants with PsO and AD.

    Rate and severity of treatment-emergent adverse events, including serious adverse events.

    Time frame: 84 days

Secondary outcomes

  1. To evaluate the plasma pharmacokinetics after multiple oral doses of LPX TI641 in participants with PsO and AD.

    Measure Area Under the Concentration Time Curve after single dose and at Steady State

    Time frame: 24 hours on Day 1 and 24 hours on Day 28

07

Study locations

3 of 3 sites recruiting
  • Red River Research Partners
    Fargo, North Dakota 58103, United States
    Recruiting
  • Clinical Investigations of Texas
    Dallas, Texas 75075, United States
    Recruiting
  • Triumpharma Clinical Research Unit at AlEssra Hospital
    Amman, Jordan B204, Jordan
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2026, 7 months after the start.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 7 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
May 21, 2025
StartActual
Jun 15, 2025
Primary completionEst.
Jan 15, 2026
CompletionEst.
Apr 15, 2026
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06982352
Lead sponsor
LAPIX Therapeutics Inc.
Responsible party
Sponsor
First posted
May 21, 2025
Start date
Jun 15, 2025
Primary completion
Jan 15, 2026 (estimated)
Completion
Apr 15, 2026 (estimated)
Last update
Dec 19, 2025

Study contacts

Anas M Fathallah, PhD
Contact
anas.fathallah@lapixtherapeutics.com
6172035516
Nimita Dave, PhD
Contact
nimita.dave@lapixtherapeutics.com
5139071470

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion